JHL Biotech Inc. aims to build a network of R&D and manufacturing facilities across Asia to develop, manufacture and commercialize affordable, high-quality biologics that meet international standards. The company is developing an internal pipeline of biosimilars. It also is working with collaborators to develop both novel biologics and biosimilars, as well as offering a broad portfolio of GMP-compliant contract manufacturing and process development services.

Most biologics manufacturing facilities in China do not comply with international GMP standards and produce versions of existing biologics that are less pure than the original products and unlikely to meet international standards as biosimilars (see BioCentury, March 18, 2013).